It’s not a question of if DJD will occur, but when.

Throughout a horse’s lifetime, joints bend, flex, bear weight and absorb shock in varying degrees. Every movement, ride or event puts “wear and tear” on the joints, reflected by the high prevalence of Degenerative Joint Disease (DJD) across the equine population. DJD is defined as “A group of disorders characterized by a common end stage in which progressive deterioration of the articular cartilage is accompanied by changes in bone and soft tissues of the joint.” Regardless of age or discipline, DJD can occur within any joint that consistently undergoes wear and tear, known as “use trauma.” This is an important reminder that joint disease can affect horses of every age and lifestyle – from top competitors and weekend warriors to backyard companions. Or, as one leading equine veterinarian so aptly put it, “If you have a horse, you have an athlete.”

Extend the patient’s “mobility span” not just life span.

Through every life stage of horses, different management strategies may be necessary to maintain soundness. As horses are living longer, veterinarians are tasked with helping maintain quality of life. Since mobility is a vital component to quality of life for every equine patient, detecting problems early and prescribing prompt treatment when disease or injury occurs is key to maximizing and maintaining healthy joints over the horse’s life span or career. Put another way, a proactive approach to diagnosis and treatment can help extend a horse’s mobility span.

### DJD RISKS THROUGH THE YEARS

<table>
<thead>
<tr>
<th>EARLY RISKS</th>
<th>MATURE RISKS</th>
<th>SENIOR RISKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Young horses may develop lameness prematurely from conformational abnormalities which can greatly influence the degree of wear and tear that a maturing joint undergoes.</td>
<td>• In healthy aging horses, lameness is the #1 concern identified by owners and veterinarians.</td>
<td>• A common cause of DJD in aged horses is osteoarthritis, or end-stage DJD.</td>
</tr>
<tr>
<td>• These abnormalities can greatly alter forces applied to joints – and can potentially lead to joint instability, injury, and DJD.</td>
<td>• Lameness is the #1 reason for loss of use and death.</td>
<td>• Older hunters or dressage horses will commonly develop front limb lameness from DJD, such as in the coffin or fetlock joints.</td>
</tr>
<tr>
<td>• In young foals and growing horses, conformation abnormalities should be addressed as early as possible.</td>
<td>• DJD is a common problem that affects the career longevity of performance horses.</td>
<td>• Several factors likely contribute to the loss of tendon and ligament resiliency in aged horses, such as impaired regenerative capacity, decreased metabolic efficiency and accumulation of products of lifelong wear and tear.</td>
</tr>
<tr>
<td>• The mature equine athlete that is performing well has likely adapted to any conformational issues that exist.</td>
<td>• Mature performance horses may experience physical changes resulting in increased risk of injury or exacerbation of chronic injury.</td>
<td>&gt; A 2018 study found an association between suspensory ligament degeneration and the age-related disease Pituitary pars intermediate dysfunction (PPID) in aged horses.</td>
</tr>
<tr>
<td>• Cutting, reining and gaited horses put significant stress on hocks and stifles early in life – locations where DJD first develops.</td>
<td>• Clients and trainers should proactively manage joint health in anticipation of senior years.</td>
<td>Focus on preserving mobility, detection of underlying medical problems.</td>
</tr>
<tr>
<td><strong>Focus on nutrition, balanced farriery, adequate training and muscle development.</strong></td>
<td><strong>Focus on avoiding injury, preserving joint health under ‘wear and tear.’</strong></td>
<td></td>
</tr>
</tbody>
</table>

### INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Mobility is longevity.™

Adequan® i.m. (polysulfated glycosaminoglycan) at every stage of life.
Start early. Stay vigilant.

The onset and progression of Degenerative Joint Disease results in the loss of cartilage components, so early intervention is important. Once diagnosis is made, develop a treatment plan focused on inhibiting the destructive processes of DJD in the beginning stages - before mobility is compromised.

Adequan® i.m. (polysulfated glycosaminoglycan) is the only FDA-Approved equine PSGAG recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. Please see accompanying Full Prescribing Information on back cover.

Adequan has been proven to work in multiple ways to maintain joint function: 6,7

Adequan® i.m. works in multiple ways to keep joints moving: 6,7

- REDUCES inflammation
- RESTORES joint lubrication
- REPAIRS cartilage
- REVERSES the disease process

Ask your veterinarian if Adequan® i.m. is right for your horse.

Inhibits enzymes that attack cartilage and synovial fluid. 6,7

Only Adequan i.m. acts as a potent enzyme inhibitor to prevent and reverse the enzyme-mediated loss of joint cartilage that occurs in DJD, which if left unchecked, results in irreversible changes to the joint. Adequan also reduces synovial fluid protein levels that are elevated in inflammation, and increases hyaluronic acid concentration in affected joints.

SELECTED IMPORTANT SAFETY INFORMATION

There are no known contraindications to the use of Adequan® i.m. and no age or breed restrictions. The safe use of Adequan® i.m. in horses used for breeding, during pregnancy or in lactating mares has not been evaluated.
Start with collaboration. Stay with it.

Whether managing a two-year old in training or a geriatric companion, proactive collaboration at all life stages between veterinarians, owners, and trainers in identifying and managing DJD is pivotal to healthy longevity. When you start with and stay with Adequan i.m., horses may enjoy greater mobility over a lifetime.¹²⁶

Discover if Adequan is the right choice for your patients.

**INDICATIONS**
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

**IMPORTANT SAFETY INFORMATION**
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. **WARNING:** Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. **CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Please see accompanying Full Prescribing Information or visit adequan.com
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.

PHARMACOLOGY: Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.

INDICATIONS: Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

DOSEAGE AND ADMINISTRATION: The recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.

CONTRAINDICATIONS: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.


PRECAUTIONS: The safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

ANIMAL SAFETY: Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

STORAGE CONDITIONS: Store at 20°-25°C (68°-77°F); (See USP Controlled Room Temperature). Discard unused portion. Dispose of spent needles in accordance with all federal, state and local environmental laws.

HOW SUPPLIED: Adequan® i.m. solution, 500 mg/5 mL (100 mg/mL) in a 5 mL single dose glass vial.

NDC 10797-995-70 5 mL Single Dose Vials Packaged 7 vials per box

AMERICAN REGENT, INC.
ANIMAL HEALTH
Shirley, NY 11967
(1-888-354-4857)

Approved by FDA under NADA # 140-901

6. Adequan® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.